Although the role of IRGM1 in neutrophils in cancer scenarios remains to be investigated, based on the recent study that the IRGM1 is required to promote T cell-mediated control of infection in neutrophils [44], and on our results that IRGM1+ neutrophils express high levels of CXCL2, CXCL10, and CXCR2, chemokines and receptors involved in neutrophil recruitment and T cell activation, we reasonably postulate that the IRGM1+ neutrophils promote anticancer immunity. The gene discussed is CXCR2; the disease is cancer.